Results 151 to 160 of about 5,892 (166)

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

British Journal of Clinical Pharmacology, 2012
Suresh Mallikaarjun, Patricia Bricmont
exaly  

Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery

General Thoracic and Cardiovascular Surgery, 2016
Yoshiki Sawa, Takashi Kido, Koichi Toda
exaly  

Tolvaptan, an Orally Active Vasopressin V2-Receptor Antagonist—Pharmacology and Clinical Trials

Cardiovascular Drug Reviews, 2007
Hiroyuki Fujiki, Yoshitaka Yamamura, Toyoki Mori   +2 more
exaly  

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial

Clinical and Experimental Nephrology, 2015
Ichiei Narita, Satoru Muto, Eiji Higashihara   +2 more
exaly  

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.

Toxicological Sciences, 2017
Paul B Watkins, Rachel J Church, Lisl K M Shoda   +2 more
exaly  

Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study

Cardiovascular Drugs and Therapy, 2011
Hidetsugu Asanoi, Takayoshi Tsutamoto
exaly  

Predictive parameter of tolvaptan effectiveness in cirrhotic ascites

Hepatology Research, 2017
Mitsuteru Kitade, Kosuke Kaji, Tadashi Namisaki   +2 more
exaly  

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

European Journal of Clinical Pharmacology, 2011
Suresh Mallikaarjun, Patricia Bricmont
exaly  

Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan

Journal of Gastroenterology, 2015
Hidetsugu Tsubouchi
exaly  

Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment

European Journal of Clinical Pharmacology, 2016
Keita Hirai, Daiki Tsuji, Kunihiko Itoh
exaly